Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.

MedStar author(s):
Citation: Journal of Thrombosis & Haemostasis. 2018 Mar 05PMID: 29504242Institution: MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2018ISSN:
  • 1538-7836
Name of journal: Journal of thrombosis and haemostasis : JTHAbstract: BACKGROUND: Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT).CONCLUSIONS: Although vasomotor symptoms have been associated with the risk of other cardiovascular events in published studies, our findings do not suggest that vasomotor symptoms are a marker of VT risk. This article is protected by copyright. All rights reserved.Copyright This article is protected by copyright. All rights reserved.METHODS: This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n=24,508) and Observational Study (n=87,783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and if so, their severity. Using Cox proportional hazards models, we estimated VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, BMI, smoking status, race/ethnicity, and time-varying current hormone therapy use.OBJECTIVE: To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables.RESULTS: At baseline, WHI Hormone Therapy Trial participants were 64 years of age and WHI Observational Study participants were 63 years of age, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1,103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (HR<sub>adj</sub> =0.91 [95%CI: 0.75, 1.1] in WHI Hormone Therapy Trials; HR<sub>adj</sub> =1.1 [95%CI: 0.99, 1.3] in WHI Observational Study) or severity (HR<sub>adj</sub> for severe vs. mild=0.99 [95%CI: 0.53, 1.9] in WHI Hormone Therapy Trials; HR<sub>adj</sub> =1.3 [95%CI: 0.89, 2.0] in WHI Observational Study) and the risk of incident VT.All authors: Allison MA, Blondon M, Cushman M, Harrington LB, Heckbert SR, Kaunitz AM, LaCroix AZ, McKnight B, Rossouw J, Smith NL, Sullivan S, Wang L, Woods NFFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-04-20
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29504242 Available 29504242

BACKGROUND: Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT).

CONCLUSIONS: Although vasomotor symptoms have been associated with the risk of other cardiovascular events in published studies, our findings do not suggest that vasomotor symptoms are a marker of VT risk. This article is protected by copyright. All rights reserved.

Copyright This article is protected by copyright. All rights reserved.

METHODS: This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n=24,508) and Observational Study (n=87,783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and if so, their severity. Using Cox proportional hazards models, we estimated VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, BMI, smoking status, race/ethnicity, and time-varying current hormone therapy use.

OBJECTIVE: To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables.

RESULTS: At baseline, WHI Hormone Therapy Trial participants were 64 years of age and WHI Observational Study participants were 63 years of age, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1,103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (HR<sub>adj</sub> =0.91 [95%CI: 0.75, 1.1] in WHI Hormone Therapy Trials; HR<sub>adj</sub> =1.1 [95%CI: 0.99, 1.3] in WHI Observational Study) or severity (HR<sub>adj</sub> for severe vs. mild=0.99 [95%CI: 0.53, 1.9] in WHI Hormone Therapy Trials; HR<sub>adj</sub> =1.3 [95%CI: 0.89, 2.0] in WHI Observational Study) and the risk of incident VT.

English

Powered by Koha